Select year

2025 2024 2023 2022 2021 Earlier

shown/page

10

2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment
International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development
Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation
ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

2025.07.09

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint
A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

2025.05.31

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma
ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025
Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation
CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

2025.03.11

AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development
AI + Chipscreen Biosciences | Technology Empowerment for Innovative Drug Development

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com